Cellphi Biotechnology AB

Cellphi Biotechnology is an early-stage biotech startup advancing innovative, cost-effective cell therapy solutions. The company focuses on immunosuppressive T-cell biology, with an emphasis on scalable and sustainable therapeutic approaches. Cellphi’s initial clinical focus is amyotrophic lateral sclerosis (ALS), a severe disease with significant unmet medical need, with broader potential applications across immune-mediated conditions.